Latest Derivatives News

Lion Rock Minerals has revealed high-grade rare earth element mineralisation starting at surface at its Minta Project in Cameroon, with assays showing up to 21.15% TREO in saprolite and a magnet-rich rare earth basket. A large-scale drilling campaign is underway to further define this significant discovery.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

Orthocell posts record FY26 revenue growth driven by expanding US and international sales of its collagen medical devices, while investing ahead in manufacturing capacity and product pipeline.

Liontown Limited (ASX:LTR) has reported its maiden profit and strong cash flow in FY26, completing its transition to fully underground mining at Kathleen Valley and advancing expansion plans with a final investment decision due early FY27.

PYC Therapeutics strengthened its financial footing with a $600 million capital raise and made notable clinical progress across four RNA therapeutic programs targeting genetic diseases.

KKR Credit Income Fund has released the audited financial statements for its core investments as of December 31, 2025, revealing mixed returns and ongoing portfolio adjustments across multiple funds.

Nanuk New World Fund delivered a robust 27.1% return for unhedged units and 36.1% for hedged units in FY2026, with net assets surpassing AUD 1.07 billion amid sustained investor demand.

Nanuk New World Fund posted robust gains in the 2026 financial year, with its hedged unit class surging 36.1% and unhedged units rising 27.1%, driven by a global equities portfolio focused on sustainability themes.

PhosCo Ltd has achieved a metallurgical breakthrough at its Gasaat Phosphate Project, producing premium-grade phosphate concentrate with a simplified flotation process, potentially unlocking significant price premiums.

Paradigm Biopharmaceuticals has surpassed its Phase 3 enrolment target for Zilosul®, secured over A$21 million in capital, and pivots towards clinical evidence generation with major data readouts expected.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.

Regal Investment Fund posted a standout FY2026 with a 17.32% net return, tripling operating profit to $117.9 million and continuing its on-market buy-back program.